{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:16:40Z","timestamp":1793395000766,"version":"4.5.0"},"reference-count":65,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,3,28]],"date-time":"2009-03-28T00:00:00Z","timestamp":1238198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Coenzyme Q<jats:sub>10<\/jats:sub> (CoQ<jats:sub>10<\/jats:sub>) and creatine are promising agents for neuroprotection in neurodegenerative diseases via their effects on improving mitochondrial function and cellular bioenergetics and their properties as antioxidants. We examined whether a combination of CoQ<jats:sub>10<\/jats:sub> with creatine can exert additive neuroprotective effects in a MPTP mouse model of Parkinson\u2019s disease, a 3\u2010NP rat model of Huntington\u2019s disease (HD) and the R6\/2 transgenic mouse model of HD. The combination of the two agents produced additive neuroprotective effects against dopamine depletion in the striatum and loss of tyrosine hydroxylase neurons in the substantia nigra pars compacta (SNpc) following chronic subcutaneous administration of MPTP. The combination treatment resulted in significant reduction in lipid peroxidation and pathologic \u03b1\u2010synuclein accumulation in the SNpc neurons of the MPTP\u2010treated mice. We also observed additive neuroprotective effects in reducing striatal lesion volumes produced by chronic subcutaneous administration of 3\u2010NP to rats. The combination treatment showed significant effects on blocking 3\u2010NP\u2010induced impairment of glutathione homeostasis and reducing lipid peroxidation and DNA oxidative damage in the striatum. Lastly, the combination of CoQ<jats:sub>10<\/jats:sub> and creatine produced additive neuroprotective effects on improving motor performance and extending survival in the transgenic R6\/2 HD mice. These findings suggest that combination therapy using CoQ<jats:sub>10<\/jats:sub> and creatine may be useful in the treatment of neurodegenerative diseases such as Parkinson\u2019s disease and HD.<\/jats:p>","DOI":"10.1111\/j.1471-4159.2009.06074.x","type":"journal-article","created":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T17:11:37Z","timestamp":1238433097000},"page":"1427-1439","source":"Crossref","is-referenced-by-count":190,"title":["Combination therapy with Coenzyme Q<sub>10<\/sub> and creatine produces additive neuroprotective effects in models of Parkinson\u2019s and Huntington\u2019s Diseases"],"prefix":"10.1111","volume":"109","author":[{"given":"Lichuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel Y.","family":"Calingasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Wille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Cormier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Flint Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)00273-8"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2001.0406"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1386"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/biof.5520180218"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.13-10-04181.1993"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360613"},{"key":"e_1_2_7_8_1","first-page":"378","article-title":"NIH announces phase III clinical trial of creatine for Parkinson\u2019s disease","volume":"22","author":"Bloom M. Z.","year":"2007","journal-title":"Consult. Pharm."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2000.0741968.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00052.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/JBB\/2006\/35936"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.05097.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M208705200"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/415096a"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0925-4439(95)00028-3"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1992.88"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1212\/01.wnl.0000187070.35365.d7","article-title":"Tolerance of high\u2010dose (3,000\u2003mg\/day) coenzyme Q10 in ALS","volume":"65","author":"Ferrante K. L.","year":"2005","journal-title":"Neurology"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409713102"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(96)00330-9"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.4.621"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3101330"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.1.3.298"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000194318.74946.b6"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2006.014"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo\u2010controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease","volume":"57","author":"Huntington\u2010Study\u2010Group","year":"2001","journal-title":"Neurology"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14660820050515205"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(90)91971-T"},{"key":"e_1_2_7_29_1","article-title":"Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer\u2019s disease","author":"Kipiani K.","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/6568"},{"key":"e_1_2_7_31_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/JNEUROSCI.20-01-00001.2000","article-title":"Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3\u2010nitropropionic acid, and 1\u2010methyl\u20104\u2010phenyl\u20101,2,5,6\u2010tetrahydropyridine","volume":"20","author":"Klivenyi P.","year":"2000","journal-title":"J. Neurosci."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1385\/JMN:21:3:191"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.02160.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2003.12.014"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05292"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(00)02038-2"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.15.8892"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-01-00156.1998"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1999.7049"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2004.04.019"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-2863(99)00033-9"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604123200"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03112.x"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000201252.57661.e1"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.3109\/10715769409145637"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2008.06.009"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(00)00020-8"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M302297200"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.07.011"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600351"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.49.343"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420221"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2006.03.004"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2004.10.021"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22023"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.7.nct60005"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200011)48:5<723::AID-ANA5>3.0.CO;2-W"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1028"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(99)00132-X"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2003.11.012"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000090629.40891.4B"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2000.740721.x"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.07.012"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-007-9033-7"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10476"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1278-04.2004"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-4159.2009.06074.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-4159.2009.06074.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T23:40:33Z","timestamp":1696981233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-4159.2009.06074.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,12]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1471-4159.2009.06074.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06074.x","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,12]]}}}